* allergy or known intolerance to pulmozyme or chinese hamster ovary cell products * history of moderate to severe asthma, cystic fibrosis, or severe copd (baseline fev1 ≤ 40% predicted) * active malignancy other than basal cell melanoma or in situ breast cancer * unstable angina * chronic liver disease as judged by the investigator that would pose significant risk to participation * chronic renal disease as judged by the investigator that would pose significant risk to participation * inability to obtain informed consent from patient or legally authorized representative (lar) * pregnant or breastfeeding use of extracorporeal membrane oxygenation (ecmo) * prisoner status * concurrent treatment with other inhaled investigational agent for covid-19\*\* * patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest) * moribund patient not expected to survive 24 hours * active hemoptysis

* allergy or known intolerance to pulmozyme or chinese hamster ovary cell products * history of moderate to severe asthma, cystic fibrosis, or severe copd (baseline fev1 ≤ 40% predicted) * active malignancy other than basal cell melanoma or in situ breast cancer * unstable angina * chronic liver disease as judged by the investigator that would pose significant risk to participation * chronic renal disease as judged by the investigator that would pose significant risk to participation * inability to obtain informed consent from patient or legally authorized representative (lar) * pregnant or breastfeeding use of extracorporeal membrane oxygenation (ecmo) * prisoner status * concurrent treatment with other inhaled investigational agent for covid-19\*\* * patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest) * moribund patient not expected to survive 24 hours * active hemoptysis

- allergy or known intolerance to pulmozyme or chinese hamster ovary cell products - history of moderate to severe asthma, cystic fibrosis, or severe copd (baseline fev1 ≤ 40% predicted) - active malignancy other than basal cell melanoma or in situ breast cancer - unstable angina - chronic liver disease as judged by the investigator that would pose significant risk to participation - chronic renal disease as judged by the investigator that would pose significant risk to participation - inability to obtain informed consent from patient or legally authorized representative (lar) - pregnant or breastfeeding use of extracorporeal membrane oxygenation (ecmo) - prisoner status - concurrent treatment with other inhaled investigational agent for covid-19** - patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest) - moribund patient not expected to survive 24 hours - active hemoptysis

- allergy or known intolerance to pulmozyme or chinese hamster ovary cell products - history of moderate to severe asthma, cystic fibrosis, or severe copd (baseline fev1 ≤ 40% predicted) - active malignancy other than basal cell melanoma or in situ breast cancer - unstable angina - chronic liver disease as judged by the investigator that would pose significant risk to participation - chronic renal disease as judged by the investigator that would pose significant risk to participation - inability to obtain informed consent from patient or legally authorized representative (lar) - pregnant or breastfeeding use of extracorporeal membrane oxygenation (ecmo) - prisoner status - concurrent treatment with other inhaled investigational agent for covid-19** - patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest) - moribund patient not expected to survive 24 hours - active hemoptysis

- allergy or known intolerance to pulmozyme or chinese hamster ovary cell products - history of moderate to severe asthma, cystic fibrosis, or severe copd (baseline fev1 ≤ 40% predicted) - active malignancy other than basal cell melanoma or in situ breast cancer - unstable angina - chronic liver disease as judged by the investigator that would pose significant risk to participation - chronic renal disease as judged by the investigator that would pose significant risk to participation - patients unable to provide informed consent or who do not have a healthcare proxy to provide consent - patients are eligible for enrollment if they are already enrolled in another interventional study that does not involved inhaled medications - pregnant or breastfeeding - use of extracorporeal membrane oxygenation (ecmo) - prisoner status

- allergy or known intolerance to pulmozyme or chinese hamster ovary cell products - history of moderate to severe asthma, cystic fibrosis, or severe copd (baseline fev1 ≤ 40% predicted) - active malignancy other than basal cell melanoma or in situ breast cancer - unstable angina - chronic liver disease as judged by the investigator that would pose significant risk to participation - chronic renal disease as judged by the investigator that would pose significant risk to participation - patients unable to provide informed consent or who do not have a healthcare proxy to provide consent - patients are eligible for enrollment if they are already enrolled in another interventional study that does not involved inhaled medications - pregnant or breastfeeding - use of extracorporeal membrane oxygenation (ecmo) - prisoner status